BioAge Labs

Filter

År

Typ

Språk

Rensa

2026-09-25 22:30:00 BioAge Labs to Present at Upcoming Investor Conferences 7,05 USD | -2,22%

2026-09-02 14:00:00 BioAge Labs to Present at Upcoming Investor Conferences 9,73 USD | +2,21%

2026-08-05 22:50:00 BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates 10,98 USD | -1,96%

2026-06-16 14:00:00 BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk 20,49 USD | +3,28%

2026-05-22 15:00:00 BioAge Labs to Present at Upcoming Investor Conferences 16,61 USD | -0,78%

2026-05-08 15:00:00 BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates 17,99 USD | +0,95%

2026-05-04 22:30:00 BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 16,62 USD | -1,01%

2026-04-21 13:00:00 BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP 19,61 USD | +4,31%

2026-04-13 22:30:00 BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference 16,19 USD | 0,00%

2026-03-24 14:00:00 BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 16,11 USD | -13,53%

2026-02-19 22:30:00 BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference 20,14 USD | +2,81%

2026-01-22 04:30:00 BioAge Announces Pricing of Upsized $115.0 Million Public Offering 18,90 USD | -6,06%

2026-01-20 22:01:00 BioAge Announces Proposed Public Offering 21,32 USD | +5,75%

2026-01-20 15:00:00 BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 21,32 USD | +5,75%

2026-01-12 15:00:00 BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk 17,85 USD | +27,23%

2025-12-04 15:00:00 BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor 10,50 USD | +13,88%

2025-11-25 22:30:00 BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference 9,00 USD | -1,53%

2025-11-07 15:00:00 BioAge Labs to Present at Jefferies Global Healthcare Conference in London 7,26 USD | -2,81%

2025-11-06 22:45:00 BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates 7,47 USD | -0,40%

2025-08-20 22:30:00 BioAge Labs to Present at Upcoming Investor Conferences 4,44 USD | +0,45%

2025-08-15 15:00:00 BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor 4,55 USD | +2,02%

2025-08-06 22:30:00 BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates 4,33 USD | -2,48%

2025-06-22 00:00:00 BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

2025-06-17 15:00:00 BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank 4,35 USD | -0,68%

2025-06-03 15:00:00 BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates 3,99 USD | -1,48%

2025-05-29 15:00:00 BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic 3,98 USD | 0,00%

2025-05-27 22:30:00 BioAge Labs to Present at Upcoming Investor Conferences 3,95 USD | -2,71%

2025-05-06 22:30:00 BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates 3,95 USD | -4,82%

2025-03-20 21:30:00 BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 4,38 USD | -1,35%

2025-02-20 22:30:00 BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference 4,40 USD | +2,33%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode